CN111249260B - 包含rpl554的液体吸入制剂 - Google Patents

包含rpl554的液体吸入制剂 Download PDF

Info

Publication number
CN111249260B
CN111249260B CN202010090019.5A CN202010090019A CN111249260B CN 111249260 B CN111249260 B CN 111249260B CN 202010090019 A CN202010090019 A CN 202010090019A CN 111249260 B CN111249260 B CN 111249260B
Authority
CN
China
Prior art keywords
rpl554
concentration
liquid pharmaceutical
pharmaceutical composition
particles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202010090019.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN111249260A (zh
Inventor
P·L·斯帕戈
E·J·弗伦奇
P·A·海伍德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Verona Pharma Ltd
Original Assignee
Verona Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1416274.7A external-priority patent/GB201416274D0/en
Priority claimed from GBGB1504662.6A external-priority patent/GB201504662D0/en
Application filed by Verona Pharma Ltd filed Critical Verona Pharma Ltd
Publication of CN111249260A publication Critical patent/CN111249260A/zh
Application granted granted Critical
Publication of CN111249260B publication Critical patent/CN111249260B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202010090019.5A 2014-09-15 2015-09-15 包含rpl554的液体吸入制剂 Active CN111249260B (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB1416274.7 2014-09-15
GBGB1416274.7A GB201416274D0 (en) 2014-09-15 2014-09-15 Formulation
GB1504662.6 2015-03-19
GBGB1504662.6A GB201504662D0 (en) 2015-03-19 2015-03-19 Formulation
CN201580053062.1A CN106794157B (zh) 2014-09-15 2015-09-15 包含rpl554的液体吸入制剂
PCT/GB2015/052668 WO2016042313A1 (en) 2014-09-15 2015-09-15 Liquid inhalation formulation comprising rpl554

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201580053062.1A Division CN106794157B (zh) 2014-09-15 2015-09-15 包含rpl554的液体吸入制剂

Publications (2)

Publication Number Publication Date
CN111249260A CN111249260A (zh) 2020-06-09
CN111249260B true CN111249260B (zh) 2023-01-10

Family

ID=54196992

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202010090019.5A Active CN111249260B (zh) 2014-09-15 2015-09-15 包含rpl554的液体吸入制剂
CN201580053062.1A Active CN106794157B (zh) 2014-09-15 2015-09-15 包含rpl554的液体吸入制剂
CN201811561721.4A Pending CN110051627A (zh) 2014-09-15 2015-09-15 包含rpl554的液体吸入制剂

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN201580053062.1A Active CN106794157B (zh) 2014-09-15 2015-09-15 包含rpl554的液体吸入制剂
CN201811561721.4A Pending CN110051627A (zh) 2014-09-15 2015-09-15 包含rpl554的液体吸入制剂

Country Status (27)

Country Link
US (2) US9956171B2 (enExample)
EP (3) EP3332767B1 (enExample)
JP (2) JP6860477B2 (enExample)
KR (1) KR102379309B1 (enExample)
CN (3) CN111249260B (enExample)
AU (3) AU2015316592B2 (enExample)
CA (1) CA2959943C (enExample)
CY (3) CY1120264T1 (enExample)
DK (3) DK3332767T3 (enExample)
ES (3) ES2875584T3 (enExample)
HK (1) HK1249415B (enExample)
HR (3) HRP20180833T1 (enExample)
HU (3) HUE045303T2 (enExample)
IL (1) IL250895B (enExample)
LT (3) LT3193835T (enExample)
MX (1) MX2017003102A (enExample)
MY (1) MY196072A (enExample)
NO (1) NO3193835T3 (enExample)
PH (1) PH12017500479B1 (enExample)
PL (3) PL3332767T3 (enExample)
PT (3) PT3494962T (enExample)
RS (3) RS57227B1 (enExample)
RU (1) RU2699995C2 (enExample)
SG (1) SG11201701854WA (enExample)
SI (3) SI3193835T1 (enExample)
SM (3) SMT202100479T1 (enExample)
WO (1) WO2016042313A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2688191C2 (ru) 2014-05-12 2019-05-21 ВЕРОНА ФАРМА ПиэЛСи Новое лечение
PL3332767T3 (pl) * 2014-09-15 2019-10-31 Verona Pharma Plc Płynna formulacja wziewna zawierająca RPL554
GB201502260D0 (en) 2015-02-11 2015-04-01 Verona Pharma Plc Salt of Pyrimido[6,1-A]Isoquinolin-4-one compound
US10947272B2 (en) 2015-07-24 2021-03-16 Hoffmann-La Roche Inc. BACE1 inhibitor peptides
GB201613054D0 (en) 2016-07-28 2016-09-14 Verona Pharma Plc New compound and process
GB2578093B (en) 2018-10-09 2020-11-18 Verona Pharma Plc Liquid pharmaceutical composition comprising RPL554 and HFA-134A
JP6994061B2 (ja) * 2019-02-15 2022-01-14 ノバルティス アーゲー ４－（７－ヒドロキシ－２－イソプロピル－４－オキソ－４ｈ－キナゾリン－３－イル）－ベンゾニトリルの製剤
GB201911517D0 (en) 2019-08-12 2019-09-25 Verona Pharma Plc Pharmaceutical composition
CA3167378A1 (en) * 2020-01-15 2021-07-22 Chia Tai Tianqing Pharmaceutical Group Co., Ltd Pharmaceutical composition of tricyclic pde3/pde4 dual inhibitor compound
GB202002786D0 (en) * 2020-02-27 2020-04-15 Verona Pharma Plc Liquid pharmaceutical composition
GB202202297D0 (en) 2022-02-21 2022-04-06 Verona Pharma Plc Formulation production process
KR20250040090A (ko) * 2022-08-08 2025-03-21 베로나 파마 피엘씨 액상 약제학적 조성물
EP4568676A1 (en) * 2022-08-08 2025-06-18 Verona Pharma PLC Ensifentrine (rpl-554) for the treatment of moderate chronic obstructive pulmonary disease (copd)
EP4609864A1 (en) * 2022-10-28 2025-09-03 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Pharmaceutical composition containing isoquinolinone compound, and preparation method therefor
EP4378942A1 (en) 2022-12-02 2024-06-05 Sandoz AG Crystal form of a pde3/4 inhibitor
WO2025003643A1 (en) * 2023-06-26 2025-01-02 Verona Pharma Plc Particulate composition comprising ensifetrine
US12194045B1 (en) 2023-06-26 2025-01-14 Verona Pharma Plc Particulate composition
WO2025052119A1 (en) * 2023-09-06 2025-03-13 Verona Pharma Plc Ensifentrine for use in treating chronic obstructive pulmonary disease (copd)
US20250249006A1 (en) * 2024-02-05 2025-08-07 Verona Pharma Plc Treatment
WO2025168708A1 (en) * 2024-02-07 2025-08-14 Verona Pharma Plc Pharmaceutical compositions of ensifentrine for chronic obstructive pulmonary disease
US20250249007A1 (en) * 2024-02-07 2025-08-07 Verona Pharma Plc Pharmaceutical compositions of ensifentrine for chronic obstructive pulmonary disease

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1348453A (zh) * 1999-03-31 2002-05-08 韦尔纳利斯有限公司 嘧啶并[6,1－a] 异喹啉－4－酮衍生物
CN1553801A (zh) * 2001-09-12 2004-12-08 含三环5,6-二氢-9H-吡唑并(3,4-C)-1,2,4-三唑并(4,3-α)嘧啶的吸入组合物
CN103313985A (zh) * 2010-08-09 2013-09-18 维罗纳制药Plc公司 嘧啶并[6,1-a]异喹啉-4-酮化合物的结晶型

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9410222D0 (en) * 1994-05-21 1994-07-06 Glaxo Wellcome Australia Ltd Medicaments
EP1033991B1 (en) * 1997-10-09 2002-04-17 Schering Corporation Mometasone furoate suspensions for nebulization
SE9704186D0 (sv) 1997-11-14 1997-11-14 Astra Ab New composition of matter
US6630169B1 (en) * 1999-03-31 2003-10-07 Nektar Therapeutics Particulate delivery systems and methods of use
GB0008660D0 (en) * 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
RU2440972C2 (ru) * 2004-12-17 2012-01-27 Сипла Лимитед Кристаллический сульфат левосальбутамола, способ его получения и фармацевтическая композиция, содержащая его
ITMI20051999A1 (it) 2005-10-21 2007-04-22 Eratech S R L Formulazioni inalatorie di farmaci in fora di polvere secca per somministrazione come tale o con nebulizzatore e dotate di elevata erogabilita' respirabilita' e stabilita'
BR112012032332A2 (pt) 2010-06-22 2016-11-08 Chiesi Farma Spa composto, uso de um composto, composição farmacêutica, combinação de um composto e dispositivo
US8778383B2 (en) * 2011-06-07 2014-07-15 Parion Sciences, Inc. Methods of treatment
US8945605B2 (en) 2011-06-07 2015-02-03 Parion Sciences, Inc. Aerosol delivery systems, compositions and methods
EP2647627A1 (en) * 2012-04-02 2013-10-09 Almirall, S.A. Salts of 5-[(1r)-2-({2-[4-(2,2-difluoro-2-phenylethoxy)phenyl] ethyl}amino)-1-hydroxyethyl]-8-hydroxyquinolin-2(1h)-one.
WO2014037727A1 (en) * 2012-09-06 2014-03-13 Verona Pharma Plc Carcainium salts
JP6560986B2 (ja) * 2013-03-15 2019-08-14 ヴェローナ ファーマ ピーエルシー 複合製剤
US10897787B2 (en) * 2014-03-11 2021-01-19 Lg Electronics Inc. Method and apparatus for device-to-device user equipment to transmit discovery signal in wireless communication system
RU2688191C2 (ru) 2014-05-12 2019-05-21 ВЕРОНА ФАРМА ПиэЛСи Новое лечение
PL3332767T3 (pl) * 2014-09-15 2019-10-31 Verona Pharma Plc Płynna formulacja wziewna zawierająca RPL554
GB201502260D0 (en) * 2015-02-11 2015-04-01 Verona Pharma Plc Salt of Pyrimido[6,1-A]Isoquinolin-4-one compound

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1348453A (zh) * 1999-03-31 2002-05-08 韦尔纳利斯有限公司 嘧啶并[6,1－a] 异喹啉－4－酮衍生物
CN1553801A (zh) * 2001-09-12 2004-12-08 含三环5,6-二氢-9H-吡唑并(3,4-C)-1,2,4-三唑并(4,3-α)嘧啶的吸入组合物
CN103313985A (zh) * 2010-08-09 2013-09-18 维罗纳制药Plc公司 嘧啶并[6,1-a]异喹啉-4-酮化合物的结晶型

Also Published As

Publication number Publication date
SMT202100479T1 (it) 2021-09-14
AU2020203081A1 (en) 2020-05-28
EP3494962B1 (en) 2021-05-26
AU2018286571B2 (en) 2020-04-02
ES2730810T3 (es) 2019-11-12
CY1124546T1 (el) 2022-07-22
CN106794157A (zh) 2017-05-31
AU2018286571A1 (en) 2019-01-24
CY1121698T1 (el) 2020-07-31
ES2670025T3 (es) 2018-05-29
RU2017108432A3 (enExample) 2019-04-01
SMT201900340T1 (it) 2019-07-11
MY196072A (en) 2023-03-13
CN111249260A (zh) 2020-06-09
SI3494962T1 (sl) 2021-09-30
AU2020203081B2 (en) 2021-08-05
NZ767295A (en) 2024-01-26
PL3193835T3 (pl) 2018-07-31
AU2015316592A1 (en) 2017-03-23
SI3193835T1 (en) 2018-06-29
NZ729796A (en) 2024-01-26
RS58897B1 (sr) 2019-08-30
CN110051627A (zh) 2019-07-26
SG11201701854WA (en) 2017-04-27
PH12017500479B1 (en) 2021-07-21
AU2015316592B2 (en) 2020-04-02
CN106794157B (zh) 2021-03-09
KR20170054406A (ko) 2017-05-17
RU2017108432A (ru) 2018-10-17
MX2017003102A (es) 2017-06-14
HUE038433T2 (hu) 2018-10-29
JP2017528479A (ja) 2017-09-28
SMT201800242T1 (it) 2018-07-17
US10945950B2 (en) 2021-03-16
KR102379309B1 (ko) 2022-03-28
HRP20211035T1 (hr) 2021-09-17
HUE045303T2 (hu) 2019-12-30
RS62252B1 (sr) 2021-09-30
PH12017500479A1 (en) 2017-07-31
IL250895B (en) 2019-08-29
PT3193835T (pt) 2018-03-27
JP2019069978A (ja) 2019-05-09
HUE055527T2 (hu) 2021-12-28
RS57227B1 (sr) 2018-07-31
HRP20191122T1 (hr) 2019-09-20
JP6795574B2 (ja) 2020-12-02
DK3193835T3 (en) 2018-05-07
EP3193835A1 (en) 2017-07-26
LT3193835T (lt) 2018-06-11
EP3193835B1 (en) 2018-03-07
DK3332767T3 (da) 2019-06-24
US20170239178A1 (en) 2017-08-24
EP3332767B1 (en) 2019-03-20
CA2959943C (en) 2022-08-16
PL3494962T3 (pl) 2021-12-06
NZ767296A (en) 2024-01-26
HK1249415B (en) 2019-11-22
CY1120264T1 (el) 2019-07-10
ES2875584T3 (es) 2021-11-10
JP6860477B2 (ja) 2021-04-14
DK3494962T3 (da) 2021-06-21
RU2699995C2 (ru) 2019-09-12
IL250895A0 (en) 2017-04-30
LT3494962T (lt) 2021-07-26
SI3332767T1 (sl) 2019-07-31
BR112017005050A2 (pt) 2018-01-23
WO2016042313A1 (en) 2016-03-24
PT3332767T (pt) 2019-06-27
PL3332767T3 (pl) 2019-10-31
HRP20180833T1 (hr) 2018-06-29
US9956171B2 (en) 2018-05-01
PT3494962T (pt) 2021-06-22
LT3332767T (lt) 2019-06-25
NO3193835T3 (enExample) 2018-08-04
CA2959943A1 (en) 2016-03-24
EP3332767A1 (en) 2018-06-13
EP3494962A1 (en) 2019-06-12
US20180369139A1 (en) 2018-12-27

Similar Documents

Publication Publication Date Title
CN111249260B (zh) 包含rpl554的液体吸入制剂
HK1249415A1 (en) Liquid inhalation formulation comprising rpl554
TW200524615A (en) Aqueous suspensions of ciclesonide for nebulisation
WO2012150131A1 (en) Improved suspension formulation of a corticosteroid for administration by inhalation
HK40007474B (en) Liquid inhalation formulation comprising rpl554
HK40007474A (en) Liquid inhalation formulation comprising rpl554
HK1233919B (en) Liquid inhalation formulation comprising rpl554
HK1233919A1 (en) Liquid inhalation formulation comprising rpl554
BR112017005050B1 (pt) Composições farmacêuticas líquidas, nebulizador e usos da composição farmacêutica líquida
HK1098486B (en) Aqueous suspensions of ciclesonide for nebulisation

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant